Reuters logo
a month ago
BRIEF-Poxel announces additional positive results for Imeglimin Phase 2b study in Japan
June 6, 2017 / 4:18 PM / a month ago

BRIEF-Poxel announces additional positive results for Imeglimin Phase 2b study in Japan

1 Min Read

June 6 (Reuters) - POXEL SA:

* POXEL ANNOUNCES ADDITIONAL POSITIVE RESULTS FOR IMEGLIMIN PHASE 2B STUDY IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES

* IMEGLIMIN PHASE 2B TRIAL IN 299 JAPANESE PATIENTS ACHIEVED STATISTICALLY SIGNIFICANT RESULTS FOR ITS PRIMARY AND SECONDARY ENDPOINTS

* SIGNIFICANT IMPROVEMENT IN LIVER FUNCTION AND SIMILAR SAFETY AND EFFICACY IN PATIENTS WITH CHRONIC KIDNEY DISEASE COMPARED TO PATIENTS WITH NORMAL RENAL FUNCTION

* POXEL SA - IMEGLIMIN PHASE 3 PROGRAM IN JAPAN IS ANTICIPATED TO BE INITIATED IN Q4 OF 2017

* IMEGLIMIN PHASE 3 PROGRAM IN JAPAN IS ANTICIPATED TO BE INITIATED IN Q4 OF 2017

* IMEGLIMIN PHASE 3 PROGRAM IN JAPAN IS ANTICIPATED TO BE INITIATED IN Q4 OF 2017

* SAYS JAPANESE DIABETES MARKET IS FAST-GROWING AND ANTICIPATED TO REACH APPROXIMATELY $6 BILLION BY 2020 SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below